Navigation Links
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)

NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. (Other OTC: RXAF.PK), announced today that effective immediately, its stock will now trade under the symbol RXAF.PK and that the name "Diamond Entertainment" and its symbol (DMON.PK) will no longer be used as part of the company's operations.

Rx for Africa, Inc. is the surviving company in a reverse merger completed in May 2007 with Diamond Entertainment Corp. - (DMON.PK). Through its wholly owned subsidiary, Rx Africa (Ethiopia) PLC (formerly known as Sunshine Pharmaceutical), Rx for Africa, Inc. owns and operates a state-of-the art pharmaceutical plant built on twenty three thousand square meters of land located south of Addis Ababa, Ethiopia. The Company is currently producing and marketing eight generic products in Ethiopia, with the goal of increasing production within the next 12 to 18 months to 50 products meeting US Food and Drug Administration (US FDA) and World Health Organization (WHO) good manufacturing practices (GMP). The expected product list includes three malaria drugs, three drugs for tuberculosis, nine HIV drugs, 27 antibiotics, and several each of anti-protozoans, anti-fungals and anti-emetics.

"The change in our name and symbol to Rx Africa, Inc. (RXAF.PK) better reflects our mission and focus as a world-class provider of generic medicines, including those for HIV/AIDS, malaria, tuberculosis and other diseases," commented Dr. Mulugetta Bezzabeh, CEO of Rx Africa (Ethiopia) PLC and board member of Rx for Africa, Inc. "Though presently focused solely in Ethiopia, we plan to expand our distribution throughout sub-Saharan Africa and beyond, and our new name and symbol are properly reflective of our path and vision. We are going to be a major player in the African pharmaceutical business."

For further information contact:

Howard Becker, Director

Rx for Africa, Inc.

(917) 553-1205

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

SOURCE Rx for Africa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
6. Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles
7. Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
8. MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy
9. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
(Date:11/25/2015)... , Nov. 25, 2015 Research and ... the "Membranes Market - Global Forecast to 2020" ... Asia-Pacific , accounting for 37.21% of the total ... Asia-Pacific region is projected to growth ... growth has been attributed primarily to the fast growing ...
(Date:11/25/2015)... , November 25, 2015 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering.  ... the addition of the  "Global Drug ...  report to their offering.  --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... Medical Solutions, one of the nation’s top ... culture with the company’s Cincinnati office being named a finalist among greater Cincinnati’s ... a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best Places to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
Breaking Medicine News(10 mins):